Market Cap | 115.51M | P/E | - | EPS this Y | 45.30% | Ern Qtrly Grth | - |
Income | -44.51M | Forward P/E | -2.63 | EPS next Y | 37.10% | 50D Avg Chg | 17.00% |
Sales | 60.9M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
Dividend | N/A | Price/Book | 25.34 | EPS next 5Y | - | 52W High Chg | -51.00% |
Recommedations | 1.80 | Quick Ratio | 2.98 | Shares Outstanding | 145.18M | 52W Low Chg | 54.00% |
Insider Own | 47.20% | ROA | -21.41% | Shares Float | 68.29M | Beta | 1.22 |
Inst Own | 34.65% | ROE | -304.17% | Shares Shorted/Prior | 324.72K/423.47K | Price | 1.47 |
Gross Margin | 77.58% | Profit Margin | -73.09% | Avg. Volume | 75,064 | Target Price | 3.10 |
Oper. Margin | -45.58% | Earnings Date | Nov 5 | Volume | 60,623 | Change | 2.80% |
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Scotiabank | Sector Outperform | Sep 16, 24 |
Craig-Hallum | Buy | Jul 26, 24 |
TD Cowen | Buy | May 13, 24 |
Lake Street | Buy | May 3, 24 |
Canaccord Genuity | Buy | Mar 4, 24 |
Canaccord Genuity | Buy | Dec 7, 23 |
Morgan Stanley | Equal-Weight | May 12, 22 |
Cowen & Co. | Outperform | Apr 20, 22 |
Morgan Stanley | Equal-Weight | Nov 17, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
SCHULER JACK W | Director Director | Aug 21 | Buy | 1.67 | 128,363 | 214,366 | 30,707,722 | 08/23/23 |
Vazquez Chris | Chief Accounting Off.. Chief Accounting Officer | Aug 08 | Sell | 1.33 | 559 | 743 | 5,865 | 08/10/23 |
Pestano Gary Anthony | Chief Development Of.. Chief Development Officer | Aug 08 | Sell | 1.33 | 1,573 | 2,092 | 103,558 | 08/10/23 |
O'Kane Kieran | Chief Commercial Off.. Chief Commercial Officer | Aug 08 | Sell | 1.33 | 1,699 | 2,260 | 46,692 | 08/10/23 |
Hutton Scott | President & CEO President & CEO | Aug 08 | Sell | 1.33 | 13,782 | 18,330 | 318,013 | 08/10/23 |
Cowie Robin Harper | CFO, Sec'y & Treasur.. CFO, Sec'y & Treasurer | Aug 08 | Sell | 1.33 | 3,577 | 4,757 | 131,535 | 08/10/23 |
SCHULER JACK W | Director Director | May 25 | Buy | 1.3575 | 52,508 | 71,280 | 20,563,212 | 05/30/23 |
SCHULER JACK W | Director Director | May 23 | Buy | 1.1459 | 56,782 | 65,066 | 20,475,396 | 05/25/23 |
Cowie Robin Harper | CFO, Sec'y & Treasur.. CFO, Sec'y & Treasurer | May 08 | Sell | 1.57 | 3,485 | 5,471 | 117,365 | 05/10/23 |
O'Kane Kieran | Chief Commercial Off.. Chief Commercial Officer | May 08 | Sell | 1.57 | 1,697 | 2,664 | 36,757 | 05/10/23 |
Siurek Ryan H | Chief Accounting Off.. Chief Accounting Officer | May 08 | Sell | 1.57 | 2,020 | 3,171 | 40,268 | 05/10/23 |
Hutton Scott | President & CEO President & CEO | May 08 | Sell | 1.57 | 13,782 | 21,638 | 240,722 | 05/10/23 |
Pestano Gary Anthony | Chief Development Of.. Chief Development Officer | May 08 | Sell | 1.57 | 1,527 | 2,397 | 99,460 | 05/10/23 |
Pestano Gary Anthony | Chief Development Of.. Chief Development Officer | Feb 08 | Sell | 1.8 | 1,852 | 3,334 | 95,933 | 02/10/23 |
Hutton Scott | President & CEO President & CEO | Feb 08 | Sell | 1.8 | 16,278 | 29,300 | 199,726 | 02/10/23 |
Siurek Ryan H | Chief Accounting Off.. Chief Accounting Officer | Feb 08 | Sell | 1.8 | 2,016 | 3,629 | 27,161 | 02/10/23 |
Cowie Robin Harper | CFO, Sec'y & Treasur.. CFO, Sec'y & Treasurer | Feb 08 | Sell | 1.8 | 4,220 | 7,596 | 99,275 | 02/10/23 |
O'Kane Kieran | Chief Commercial Off.. Chief Commercial Officer | Feb 08 | Sell | 1.8 | 1,999 | 3,598 | 22,993 | 02/10/23 |
Kennedy Lawrence T. Jr | 10% Owner 10% Owner | Nov 21 | Buy | 1.15 | 10,869,565 | 12,500,000 | 4,355,914 | 01/05/23 |
O'Kane Kieran | Chief Commercial Off.. Chief Commercial Officer | Nov 08 | Sell | 1.03 | 1,705 | 1,756 | 15,184 | 11/10/22 |
Georgantas Robert William III | Chief Scientific Off.. Chief Scientific Officer | Nov 08 | Sell | 1.03 | 1,776 | 1,829 | 26,114 | 11/10/22 |
Hutton Scott | President & CEO President & CEO | Nov 08 | Sell | 1.03 | 13,777 | 14,190 | 106,010 | 11/10/22 |
Cowie Robin Harper | CFO, Sec'y & Treasur.. CFO, Sec'y & Treasurer | Nov 08 | Sell | 1.03 | 3,582 | 3,689 | 74,529 | 11/10/22 |
Pestano Gary Anthony | Chief Development Of.. Chief Development Officer | Nov 08 | Sell | 1.03 | 1,580 | 1,627 | 92,732 | 11/10/22 |
Siurek Ryan H | Chief Accounting Off.. Chief Accounting Officer | Nov 08 | Sell | 1.03 | 1,725 | 1,777 | 14,999 | 11/10/22 |
Siurek Ryan H | Chief Accounting Off.. Chief Accounting Officer | Aug 08 | Sell | 2.53 | 1,645 | 4,162 | 11,242 | 08/10/22 |
Hutton Scott | President & CEO President & CEO | Aug 08 | Sell | 2.53 | 13,634 | 34,494 | 75,009 | 08/10/22 |
Georgantas Robert William III | Chief Scientific Off.. Chief Scientific Officer | Aug 08 | Sell | 2.53 | 1,686 | 4,266 | 22,244 | 08/10/22 |
Cowie Robin Harper | CFO, Sec'y & Treasur.. CFO, Sec'y & Treasurer | Aug 08 | Sell | 2.53 | 3,533 | 8,938 | 66,537 | 08/10/22 |
Pestano Gary Anthony | Chief Development Of.. Chief Development Officer | Aug 08 | Sell | 2.53 | 1,549 | 3,919 | 89,258 | 08/10/22 |
O'Kane Kieran | Chief Commercial Off.. Chief Commercial Officer | Aug 08 | Sell | 2.53 | 1,673 | 4,233 | 11,428 | 08/10/22 |
O'Kane Kieran | Chief Commercial Off.. Chief Commercial Officer | May 09 | Sell | 1.83 | 1,583 | 2,897 | 7,639 | 05/11/22 |
Siurek Ryan H | Chief Accounting Off.. Chief Accounting Officer | May 09 | Sell | 1.83 | 1,947 | 3,563 | 7,403 | 05/11/22 |
Georgantas Robert William III | Chief Scientific Off.. Chief Scientific Officer | May 09 | Sell | 1.83 | 2,004 | 3,667 | 18,283 | 05/11/22 |
Hutton Scott | President & CEO President & CEO | May 09 | Sell | 1.83 | 13,278 | 24,299 | 43,866 | 05/11/22 |
Pestano Gary Anthony | Chief Development Of.. Chief Development Officer | May 09 | Sell | 1.83 | 1,467 | 2,685 | 85,753 | 05/11/22 |
Cowie Robin Harper | CFO, Sec'y & Treasur.. CFO, Sec'y & Treasurer | May 09 | Sell | 1.83 | 3,338 | 6,109 | 58,495 | 05/11/22 |
PATIENCE JOHN | - - | Apr 07 | Buy | 1.79 | 279,329 | 499,999 | 337,926 | 04/11/22 |
Strobeck Matthew | Director Director | Apr 07 | Buy | 1.79 | 1,117,318 | 1,999,999 | 769,859 | 04/11/22 |
SCHULER JACK W | Director Director | Apr 07 | Buy | 1.79 | 2,793,296 | 5,000,000 | 11,256,460 | 04/11/22 |
SCHULER JACK W | Director Director | Dec 30 | Buy | 4.35 | 2,298,850 | 9,999,998 | 8,463,164 | 01/31/22 |
Cowie Robin Harper | CFO, Sec'y & Treasur.. CFO, Sec'y & Treasurer | Jan 13 | Option | 0.42 | 5,679 | 2,385 | 47,654 | 01/18/22 |